State Board of Health pauses new additions to newborn screening for 12 months amid $5.1M shortfall
Loading...
Summary
The Washington State Board of Health voted to pause policy activity to add new conditions to the newborn screening panel and to halt convening new technical advisory committees for 12 months starting 2026‑07‑01, responding to a Department of Health funding gap the agency estimated at about $5.1 million.
The Washington State Board of Health voted to pause adding any new conditions to the state’s newborn screening panel and to delay convening technical advisory committees for 12 months, starting July 1, 2026. The action followed a Department of Health briefing that the newborn screening program faces an estimated $5.1 million budget shortfall.
Anna Pickett, acting director for the newborn screening program at the Department of Health, told the board that the program is “facing a relatively large budget shortfall of about $5,100,000,” and that DOH is requesting a one‑year pause on adding new conditions and convening new technical advisory committees to allow time to pursue funding and to develop an implementation plan.
Board members debated the tradeoffs. Some said the pause is necessary to preserve the program’s current operations while the department seeks additional funding; others warned the delay could worry families and advocates. Vice Chair Kelly Oshiro framed the board’s role as procedural: the board can decline rulemaking petitions and set timelines for implementation while DOH pursues fiscal remedies.
Member Peter Browning supported the pause as a practical response to the fiscal reality, noting the importance of presenting a clear, unified picture of public‑health capacity to the Legislature. Chair Patty Hayes underscored the board’s request that DOH come back to the June meeting with a work plan describing next steps and potential legislative requests.
The motion to pause policy activity for 12 months beginning 2026‑07‑01 passed after discussion; DOH was directed to return to the board in June with an updated plan and to explore a fee increase and other funding options.
The pause affects the initiation of rulemaking steps (CR101/CR102/CR103 filings) for new newborn screening conditions and the convening of new technical advisory committees during the one‑year window. Already‑implemented additions to the panel were not reversed.
DOH and board staff said they would communicate details of the decision and next steps to families, clinical partners, and legislators as they pursue funding options.
